LOS ANGELES–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) presented data from its groundbreaking online survey of gay men which raised questions about the use of Gilead Sciences’ Truvada for HIV prevention. The data was presented at the HIV PrEP Symposium at UCLA last week. Sponsored by the UCLA School of Public Health, the Reproductive Health Interest Group and AIDS Healthcare Foundation, the event sought to explore issues surrounding the use of Truvada as a pre-exposure prophylaxis or PrEP. AHF’s online focus group survey was designed to determine “real world” reactions from prospective consumers about the use of an HIV prevention pill.
For more information, please visit: www.nomagicpills.org.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6733260&lang=en.